TreatMent Of Knee osTeoarthritis wIth chONdroitin Sulfate - the OA MOTION Study — MOTION  

Knee Osteoarthritis Clinical Trial

Official title: A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Chondroitin Sulfate 800 mg Tablets Versus Placebo in Subjects With Pain Due to Knee Osteoarthritis and to Evaluate the Durability of the Effect and Safety of the Treatment

Status Withdrawn

Clinical Trial Summary

The goal of this phase III study is to evaluate the efficacy, safety, and tolerability of chondroitin sulfate 800 mg oral tablets versus placebo in the treatment of subjects with pain due to knee OA (osteoarthritis). The further aims of the study are to evaluate the durability of the treatment effect (up to week 36) and to gain further long-term safety and efficacy data (up to 48 weeks). The primary outcome of interest will be the effect of chondroitin sulfate on pain in the index knee at week 24 compared to placebo. The effect of chondroitin sulfate in the index knee functionality and the patient global impression of changes at 24 weeks compared to placebo are included as key-secondary endpoints. An additional key secondary endpoint will assess the durability of the effect on pain compared to placebo at week 36. Several additional secondary endpoints are included to further support the beneficial effect of the treatment and the improvements in patient's quality of life (i.e., Western Ontario and McMaster Universities Arthritis Index -WOMAC- subscales and total scores at each study visits, changes in patient's quality of life, use of rescue medication etc.) other than the safety of the product.

Clinical Trial Description

The goal of this phase III study is to evaluate the efficacy, safety, and tolerability of chondroitin sulfate 800 mg oral tablets versus placebo in the treatment of subjects with pain due to knee OA (osteoarthritis). The further aims of the study are to evaluate the durability of the treatment effect (up to week 36) and to gain further long-term safety and efficacy data (up to 48 weeks). Approximately 690 male and female adult subjects with moderate-to-severe pain due to OA of the knee will be randomized in a 1:1 ratio to receive either chondroitin sulfate 800 mg tablets (CS) or matching placebo. Subjects will orally self administer chondroitin sulfate/placebo once daily at home during the double blind treatment period of 36 weeks. The first approximately 250 subjects who reach Week 36 and are willing to further participate in the study will attend a double blind long-term safety follow-up period and will continue to self administer chondroitin sulfate/placebo for 12 additional weeks (up to week48). Acetaminophen 500 mg oral tablets, max. 6 tablets per day (rescue medication), will be the only analgesic allowed for the clinical study to treat pain of any type. The study will include the following endpoints: Primary Efficacy (Double-blind Treatment Period until Week 36) • Change from Baseline to Week 24 in the weekly mean of the average daily pain in the index knee as measured by the numerical rating scale (NRS) (0 10 points) Key Secondary Efficacy (Double-blind Treatment Period until Week 36) - Change from Baseline to Week 24 in Western Ontario and McMaster Universities Arthritis Index (WOMAC) function subscale - Subject's global evaluation at Week 24 as measured by Patient Global Impression of Change (PGIC) - Change from Baseline to Week 36 in the weekly mean of the average daily pain in the index knee as measured with the NRS (durability of effect) Other Secondary Efficacy (Double-blind Treatment Period until Week 36) - Change from Baseline to each week until Week 36 in the weekly mean of the average daily pain in the index knee as measured with the NRS - Change from Baseline to Weeks 4, 12, 24, and 36 in WOMAC total score and all WOMAC subscores - Consumption of rescue medication (acetaminophen), including the number of intake days, number of daily intakes, and total dose per day - Change from Baseline to Weeks 4, 12, 24, and 36 in subject's quality of life (Short Form 36 Health Survey Questionnaire [SF-36]) - Subject's global evaluation at Weeks 4, 12, and 36 as measured by PGIC - Investigator's global evaluation at Weeks 4, 12, 24, and 36 by Clinician Global Impression of Change (CGIC) - Responder rates at each visit using 2 different response definitions (≥30% or ≥50% decrease in weekly mean of the average daily [24 hour] NRS pain intensity score) Safety and Tolerability (Double-blind Treatment Period until Week 36) - Number of subjects with any adverse events (AEs), treatment emergent adverse events (TEAEs), AEs causally related to the investigational product (IP) (ADRs), and serious adverse events (SAEs) - Number of dropouts due to AEs and dropouts due to AEs causally related to the IP (ADRs) - IP Compliance - Subject's treatment satisfaction as measured by the Medication Satisfaction Questionnaire (MSQ) at Weeks 4, 12, 24, and 36 - Change in laboratory parameters from Baseline to Weeks 4, 12, 24, and 36 - Change in 12 lead electrocardiogram (ECG) parameters from Baseline to Week 24 - Change in vital signs from Baseline to each post-baseline visit Safety Follow-up Period from Weeks 36 to 48 with Continued Double-blind Treatment for those subjects who continue in the study until Week 48 (planned number: approximately 250 subjects) Primary Safety • Number of subjects with any AEs, TEAEs, ADRs, and SAEs Secondary Safety - Changes from Baseline to Week 48 in vital signs, ECG, and safety laboratory results - Changes from Baseline to Week 48 in subject's treatment satisfaction as measured by the MSQ Exploratory Efficacy - To explore the long-term efficacy of once daily treatment with CS 800 mg oral tablets - Change from Baseline to Week 48 in the weekly mean of the average daily pain in the index knee as measured by the NRS (0 10 points) - Change from Baseline to Week 48 in WOMAC total score and all subscale scores - Change from Baseline to Week 48 in subject's quality of life (SF-36) - Subject's global evaluation as measured by PGIC at Week 48 - Investigator's global evaluation as measured by CGIC at Week 48 Subjects will use an eDiary (electronic diary) to record, daily, their average daily pain in the index knee (by a numerical rating scale) and to record the daily administration of the IP and the frequency and dose of rescue medication taken. To enter the study, subjects must be outpatients ≥50 years of age and have a documented diagnosis of OA in the index knee, based on the American College of Rheumatology (ACR) Criteria for Classification of Idiopathic OA of the knee. Subjects will not be eligible if they have ≥1 pain score reported as 10 on the NRS during the 7 days prior to randomization (Day 1). For subjects with bilateral knee pain, the more symptomatic knee (i.e., the more painful knee) will be determined by the investigator together with the subject as the index knee during the Screening Visit. The screening period of the study will include a washout from analgesics and from other drugs taken for pain (i.e nonsteroidal anti-inflammatory drug) that will be followed by a Run-in Period (Day 7 to Day 1) with a total duration of up to 21 days before randomization. Subjects will return to the study site on Day 1 (Baseline), at Weeks 4 (Day 28), 8 (Day 56), 12 (Day 84), 16 (Day 112), 20 (Day 140), 24 (Day 168), and 36 (Day 252) during the double-blind treatment period of 36 weeks to complete the efficacy, safety, and tolerability assessments as applicable. In addition, those approximately 250 subjects who participate in the safety follow up period will return to the site at Week 48 (Day 336). Regular telephone contacts will occur every 2 weeks between scheduled visits during the double-blind treatment and safety follow-up periods to assess the adverse events and to verify treatment compliance. ;

Related Conditions & MeSH terms

• Knee Osteoarthritis
• Osteoarthritis
• Osteoarthritis, Knee

• NCT number: NCT05632783
• Study type: Interventional
• Source: IBSA Institut Biochimique SA
• Status: Withdrawn
• Phase: Phase 3
• Start date: December 2023
• Completion date: July 2026